Advertisement
Screener

PTC Therapeutics, Inc. (PTCT) Deferred Revenue

2.8 / 5 stars · 68/120 Roast Me

PTC Therapeutics, Inc. Deferred Revenue

PTC Therapeutics, Inc. (PTCT) had Deferred Revenue of $0 as of 2018-03-31, per its 10-Q filed 2018-05-09.

Discontinued › Balance Sheet › Liabilities › Liabilities, Current

us-gaap:DeferredRevenueCurrent · last filed 2018-05-09

  • 2018-03-31: Deferred Revenue, Current $0.00.
  • 2017-12-31: Deferred Revenue, Current $3.94M.
  • 2017-09-30: Deferred Revenue, Current $6.12M.
  • 2017-06-30: Deferred Revenue, Current $2.60M.
Period endDeferred Revenue, CurrentDeferred Revenue, Current as first filed
2018-03-31$0.00
10-Q · filed 2018-05-09
2017-12-31$3.94M
10-Q · filed 2018-05-09
2017-09-30$6.12M
10-Q · filed 2017-11-02
2017-06-30$2.60M
10-Q · filed 2017-08-09
2016-12-31$0.00
10-K · filed 2018-03-06
2016-09-30$910.00K
10-Q · filed 2016-11-03
2016-06-30$726.00K
10-Q · filed 2016-08-04
2016-03-31$396.00K
10-Q · filed 2016-05-05
2015-12-31$139.00K
10-K · filed 2017-03-16
2015-03-31$373.00K
10-Q · filed 2015-05-05
2014-12-31$3.35M
10-K · filed 2016-02-29
2014-09-30$769.00K
10-Q · filed 2014-11-06
2014-06-30$242.00K
10-Q · filed 2014-08-07
2014-03-31$492.00K
10-Q · filed 2014-05-06
2013-12-31$878.00K
10-K · filed 2015-03-02
$877.43K
10-K · filed 2014-03-06
2013-09-30$3.63M
10-Q · filed 2013-11-14
2013-06-30$6.98M
10-Q · filed 2013-08-13
2012-12-31$16.69M
10-K · filed 2014-03-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
Dianthus Therapeutics, Inc. /DE/ (DNTH)United States$5.082B-27.79
Erasca, Inc. (ERAS)United States$5.073B-19.96
Gossamer Bio, Inc. (GOSS)United States$5.355B-0.65
Cogent Biosciences, Inc. (COGT)United States$5.450B-17.61
Veradermics, Inc (MANE)United States$4.839B
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Edgewise Therapeutics, Inc. (EWTX)United States$4.470B-22.23
Viking Therapeutics, Inc. (VKTX)United States$4.287B-8.51